Glaxosmithkline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

Established in the year 1924 in India, GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3,500 people. Globally, the company is a £28.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs 2080 crore and a share of 5.1%. GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

The company leads in several therapeutic segments - dermatology, anti-helmentics, and hormones. It has 7 products in the top 50 brands, and the top five GSK products are Augmentin, Calpol, Ceftum, Phexin, and Betnesol. The company's vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix, Rotarix, Hiberix and Cervarix.

GSK India's R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India. The number of clinical studies conducted in India is rapidly growing across a range of therapy areas. The company's social responsibility programmes focus on development of under developed villages, women, children and aged, specifically in the areas of healthcare and education.

The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.

The company's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. The company has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk drugs and the active pharmaceutical ingredients are manufactured at Thane.

Products

Prescription medicines

The GSK India product portfolio includes prescription medicines and vaccines. The company is a market leader in most of the prescription medicines.

·      Analgesic

·      Anti-Infective

·      Anti-Inflammatory

·      Anti-Parasitic

·      Cardiovascular

·      Dermatology

·      Diabetes

·      Endocrine

·      Gastrointestinal

·      Gynaecology

·      Immunosupressants

·      Nutritional

·      Respiratory

·      CNS

·      Oncology

Vaccines

The company's vaccines division is the leader in fast growing vaccine market. It provides vaccines for prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Brands like Engerix-B, Havrix, Priorix, Twinrix are some vaccines created by GSK India.

The company was awarded  for the “Multi Cultural Diversity Award” from GlaxoSmithKline Consumer Healthcare, US as an appreciation for the ‘Famili Vaccines’ Programme. The company in 2008 launched two vaccines for dphtheria, ttanus and acellular prtussis (DTP) namely Boostrix and Infanrix. DTP vaccines are part of the routine immunization in over 100 developed and developing countries.

Infanrix is used for childhood immunization against Diphtheria, Tetanus and Pertussis for newborns from the sixth week of age. Boostrix is used for children above seven years of age, adolescents and adults and will boost the waning immunity against Diphtheria, Tetanus and Pertussis.

Milestones

1919 - Trading links with India established

1924 - H J Foster & Co appointed sole agents

1926 - Foster's becomes wholly-owned subsidiary of Joseph Nathan

1947 - Secondary manufacture commences after war

1950

·      Name changed to Glaxo Laboratories

·      SmithKline & French appoints its first medical representative

1956 - Primary production of vaccines begins at Worli

1960's

·      Infant foods manufactured at milk drying plant at Aligarh

·      Manufacturing facility for pharmaceuticals opened in Mumbai

1961 - Vitamin A and betamethasone manufactured at new plant at Thane using imported raw materials

1968 - Registered as a limited company. Animal health products introduced

1969 - Indian shareholders acquire 25 per cent of the company's equity

1971

·      Research and development laboratory built at Thane

·      Relocation of the SmithKline and French plant from Mumbai to Bangalore

1983 - Glaxo Group equity reduced from 75 per cent to 40 per cent Nashik factory commissioned

1984 - SmithKline & Beecham becomes a public limited company under the new name of Eskayef Limited. Plant set up in Mysore for manufacture of bulk drugs

1985 - The company's second basic drugs factory was inaugurated at Ankleshwar, Gujarat

1986 - Joint venture projects Vegepro Foods and Feeds Limited and K G Gluco Biols were launched with equity participation of around 24 per cent by Glaxo India

1987 - The company's name changed to Glindia Limited

1988

·      Production of bulk drug Ranitidine commenced at Ankleshwar

·      Hindustan Foods Limited, a joint venture project for the manufacture of extruded foods, was commissioned at Usgao, Goa with equity participation of 20 per cent by Glaxo and its subsidiaries

1989

·      Production of Zinetac at Nashik commenced

·      The company's name changed to Glaxo India Limited

1990

·      Production of the bulk drug, cephalexin, commenced at Ankleshwar and the salbutamol inhalers at Nashik

·      Glaxo rated amongst the first five of India's most respected companies (4th place), in a survey by Businessworld magazine

1991

·      An agreement was signed with the Council of Scientific and Industrial Research

·      Production of the bulk drug Griseofulvin commenced at Ankleshwar

·      Facilities commissioned at Nashik for the sterile dry filling of the injectable cephalosporins cefuroxime sodium and ceftazidime pentahydrate

1992

·      Liquid injectables block commissioned at Nashik

·      The company's trade investment in Vegepro and Feeds Limited was sold

1993

·      Glaxo Group raised its equity from 40 per cent to 51 per cent

·      The company sold its investment in Hindustan Foods Limited and Dempo Dairy Industries Limited

·      Cetzine, a second generation anti-histamine, and research product of UCB Pharma (Belgium), was launched under a co-marketing agreement

·      The company launched two anti-TB products - Zucox and Rizap

·      Manufacture of Beclomethasone inhalers commenced at Nashik

·      Thane Factory's new fermentation plan was inaugurated, making this site the largest Betamethasone producer in Glaxo Group

·      The company received recognition from the Ministry of Commerce as an export house

1994

·      Glaxo - Ankleshwar wins the Chief Executive's Trophy for Health Safety and Environment Management

·      Glaxo rated as India's 44th most valuable company in a survey conducted by Business Today

·      The company sold its Family Products Division to H J Heinz for a sum of Rs 210 crores. A formal agreement between the companies was signed and transaction was completed in October

1995

·      Glaxo - Thane won the Chief Executive's Trophy for Health Safety and Environmental Management

·      The company declares a Bonus in the ratio of 1:1

·      Voluntary Retirement Scheme introduced for Management Staff 1996 - 175 per cent record dividend declared

·      Change in distribution system - a Voluntary Retirement Scheme introduced at Branches and Depots

·      Government approved state-of-the-art Pharmacy Research & Development Centre (PR&D) inaugurated at Thane to cater to the unmet medical needs and to exploit local commercial opportunities

·      Glaxo rated amongst the top ten of India's most respected companies (8th place) in the Business World - Marg survey

·      Glaxo wins 'Marketing Company of the Year' award from the Institute of Marketing & Management (IMM)

·      Glaxo wins 'The Analyst' award from Chartered Analyst magazine as an investor rewarding company.

·      SmithKline Beechams Bangalore plant awarded the ISO 9002 certification

1997

·      Voluntary Retirement Scheme introduced for workmen at Worli and Thane

·      Glaxo acquires Biddle Sawyer Group of Companies subject to statutory approvals

1998

·      Biddle Sawyer acquisition is completed

·      Worli factory completes two million man-hours free from lost time accident

·      Gramin Arogya Vikas Sanstha - a rural development programme initiated in Nashik

·      Glaxo ranks 21st in Business Today's list of 500 most valuable companies

1999

·      Glaxo India completes 75 years of its operations in India

·      Glaxo India ranked as India's Most Respected Company by BusinessWorld. Glaxo took the top honour from amongst 229 companies surveyed by BusinessWorld - Indica Research

·      Glaxo India wins two Chairman's Awards for the year 1998 (announced in 1999) - The company's Community Support Programme won the Chairman's Award for 'Excellence in Corporate Citizenship' and Glaxo India's Nashik Factory was chosen for the Health, Safety and Environmental Management Award

·      Nashik factory completes three million man-hours free from lost time accidents

·      Winner of the 1999 IMM (Institute of Marketing and Management) Award for Excellence as Marketing Company (organised sector)

·      The company's HIV / AIDS campaign in Press wins the first prize for the best 'Social Responsibility Communication', awarded by the Association of Business Communicators of India (ABCI)

·      The Positive People Campaign entitled 'Real Friendships Don't Die with HIV' also wins the Global Award from the New York Festivals

2000

·      Agrivet Farm Care (AFC) tied up with Merial, the world's largest Animal Health Company, to market poultry vaccines

·      Glaxo India ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth Creator Companies

·      Launches Seretide for Asthma

2001

·      Merger of SmithKline Beecham Pharmaceuticals (India) Limited into Glaxo India Limited. The name of the company changed to GlaxoSmithKline Pharmaceuticals Limited in India

2002

·      J P Garnier inaugurates GSK House

·      VRS at the Ankleshwar site and sale of Ankleshwar property to Glenmark Pharmaceuticals Limited

2003

·      GlaxoSmithKline named as India's most respected Pharmaceutical Company in a survey conducted by BusinessWorld and the Indian Market Research Bureau (IMRB)

·      Launches Cetzine (cetirizine; anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate; nutritional), Cobadex CZS (multivitamin with trace elements)

2004

·      Augmentin becomes the No. 1 pharmaceutical brand, as rated by IMS

·      Launches Priorix (measles, mumps, rubella vaccine)

·      Receives prestigious Multi Cultural Diversity Award from GlaxoSmithKline Consumer Healthcare Limited, U.S. for the Famili Vaccines programme, selected from 83 entries received from markets world-wide

2005

·      Foundation stone laid for GSK vaccines plant at Nashik

·      Launch of oral contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only pill)

·      Enters the diabetes therapeutic segment with the launch of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin)

2006

·      Augmentin grows to a Rs. 100 crore brand

·      In-licensing alliance with Eisai Pharmaceuticals, Japan and launch of Parit (rabeprazole; gastrointestinal therapy area)

·      GlaxoSmithKline divests its Agrivet Farm Care (AFC) Business

2007

·      Launches Carzec (carvedilol) and Zemetril (cefprozil)

·      GlaxoSmithKline divests its Qualigens Fine Chemicals (QFC) Business

·      Launches Arixtra (fondaparinux sodium), an antithrombotic drug used in treating Deep Vein Thromb sis (DVT) and Acute Coronary Syndrome (ACS)

2008

·      Launches Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed), Infanrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed) and Rotarix (Human Rotavirus Vaccine, Live Attenuated) vaccines

·      Launches Tykerb, a drug in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2+/neu (ErbB2+) and who have failed on prior therapy including trastuzumab

·  Launches Benitec (Olmersartan) and Benitec-H (Olmesartan + Hydrochlorothiazide) an anti-hypertensive drug in-licensed from Daiichi Sankyo Company Limited, Japan

2009

• Launches Cervarix [Human Papillomavirus (Types 16 and 18)] vaccine
• Launches Dermocalm for treatment of Dry Itchy skin
• Commences Albendazole production in Nashik to treat Lymphatic Filariasis

2010

• Launches Mycamine an injectible antifungal drug in-licensed from Astellas, Japan
• Andrew Witty dedicates the Albendazole facility at Nashik to WHO to eliminate Lymphatic FilariasisCertificate of Merit awarded to Ankleshwar Factory for 'Excellence in Energy Conservation' by the Federation of Gujarat Mills and Industries (FGMI)
• Voluntary Retirement Scheme introduced for Glaxo workmen
• Eskayef Limited renamed SmithKline Beecham Pharmaceuticals India Ltd,
• The Mysore plant receives ISO 9002 certification
• The new Iodex plant inaugurated in Bangalore

2011

• Most Respected Company Award - Business World
• Launches Votrientâ„¢ indicated for the treatment of advanced renal cell carcinoma (RCC)
• Launches Revoladeâ„¢ indicated for the treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP)
• Vaccine Market Company of the Year award - Frost & Sullivan
• Special Commendation - Good Corporate Citizen Award 2011 - Bombay Chamber of Commerce
• Pharma / Life - Science Supply Chain Excellence Award presented at the 5thExpress, Logistics and Supply Chain Conclave
  Unveils Synflorix - a vaccine against invasive pneumococcal disease

2012

• Launches Altargoâ„¢ used to treat bacterial infections affecting small areas of skin
• Introduces Volibris (Ambrisentan), a non-sulphonamide class endothelin receptor antagonist (ERA) used to treat pulmonary arterial hypertension (PAH) indicated for WHO Functional Class II & III patients in India. Volibris® is a trademark of GlaxoSmithKline. Ambrisentan has been licensed to GlaxoSmithKline by Gilead Sciences Inc.
• GSK India named as India's most admired company in Pharmaceutical space by HAY Group and Fortune Magazine.
• Awarded the Paediatrician's Award for the Best Vaccine Company of the Year by Frost & Sullivan.
• Received the Dr. H. R. Nanji Memorial Marketing Excellence Award for CCM in the 'Existing Pharmaceuticals Product' category from OPPI (Organisation of Pharmaceutical Producers of India)

2013

• Fourth CII National HR Excellence Award 2013 for 'Significant achievement in HR Excellence'
• GSK India named as one of 'India's Most Admired Companies' by Fortune India & HAY Group
• Business Today survey in partnership with PeopleStrong HR Services named GSK India as one of the 'Best Companies to work for'

Market Cap: 24,017 Cr.
Current Price: 1,418
52 weeks High / Low 1812.00 / 1020.00
Book Value: 112.86
Stock P/E: 60.42
Dividend Yield: 1.23 %
ROCE: 25.61 %
ROE: 16.67 %
Sales Growth (3Yrs): -4.41 %
Listed on BSE and NSE
Company Website
Face Value: 10.00


Industry PBV:
EPS: 22.70
Graham: 240.09
Debt to equity: 0.00
Book value: 112.86
Price to Earning: 60.42
PEG Ratio: -4.77
Earning Power: 15.56 %
Return on equity: 16.67 %
Pledged percentage: 0.00 %
Intrinsic Value: -1,733.38
Industry PE:
Piotroski score: 7.00
Volume: 6,566
Market cap to quarterly profit: 221.62
Market Capitalization: 24,017 Cr.
Price to book value: 12.56
Return on assets: 14.65 %
Debt: 0.99 Cr.
Interest Coverage Ratio: 1,015
Promoter holding: 75.00 %
Unpledged promoter holding: 75.00 %

Thomas Cook (India) Ltd.

Thomas Cook (India) Ltd.

Thomas Cook India (TCIL) is India’s largest travel and financial services company. The Company launched its Indian operation in 1881.

Currently, it has presence in 55 cities spreading across 200 locations. On pan India level, the company has office located at Mumbai, Pune, New Delhi, Gurgaon, Chandigarh, Agra, Ahmedabad, Bangalore, Baroda, Bhubhaneshwar, Chennai, Cochin, Goa, Hyderabad, Jaipur, Jalandhar, Kolkata, Trivandrum and Vishakapatnam.

With 125 year of presence in India TCIL is focused on providing a broad spectrum of travel-related services that include foreign exchange, corporate travel, leisure travel, and insurance.

The company’s overseas subsidiaries offices are located at Sri Lanka, Mauritius, Germany, France, Spain, Canada, UK, USA, Australia, Japan, Korea and China.

The company has employee strength of 3000 people.

Business division

Travel- The company provides different travelling destinations for domestic inbound/ outbound holidays. The company operates over 40 Group Inclusive Tours (GIT) spread across 5 continents.

Corporate Travel Management- The Company provides travel solutions and travel budgets of several large national and multinational companies

Foreign Exchange- The company is leading foreign exchange provider offering wide range of product and services.

Travel Insurance- Being the only travel company that has license to sell insurance co-brand travel insurance products with TATA AIG General Insurance Company.

Awards

The company received Golden Peacock Award for Excellence in Corporate Governance 2006.

TCIL was awarded Best Technology Award, 2005 by Galileo Express Travel and Tourism Award for Best Technology Programme.

Outlook

The company has entered into tie up with with cruise line operator Indian Ocean Cruises of London based Foresight Smart Ventures in order to market heritage cruise Ms Ocean Odyssey in India and Mauritius. -


Market Cap: 8,524 Cr.
Current Price: 229.95
52 weeks High / Low 302.90 / 193.10
Book Value: 239.96
Stock P/E: 68.41
Dividend Yield: 0.16 %
ROCE: 103 %
ROE: 117 %
Sales Growth (3Yrs): 51.35 %
Listed on BSE and NSE
Company Website
Face Value: 1.00
Industry PBV:
EPS: 162.43
Graham: 936.47
Debt to equity: 0.05
Book value: 239.96
Price to Earning: 68.41
PEG Ratio: 0.43
Earning Power: 2.08 %
Return on equity: 117 %
Pledged percentage: 0.00 %
Intrinsic Value: 1,119
Industry PE:
Piotroski score: 4.00
Volume: 75,628
Market cap to quarterly profit: -1,008.76
Market Capitalization: 8,524 Cr.
Price to book value: 0.96
Return on assets: 86.96 %
Debt: 424.71 Cr.
Interest Coverage Ratio: 2.29
Promoter holding: 66.98 %
Unpledged promoter holding: 66.98 %

Bayer CropScience Ltd

Bayer CropScience Ltd

Bayer CropScience incorporated in the year 1958; is engaged in manufacturing of crop protection products, non agricultural pest-control, seeds and plant biotechnology.

The company was earlier known as Bayer (India). In the year 1924, the company set up Bayer crop protection research department. Later in 1951 the company launched its first systemic insecticide Systox (demeton).

Being part of Bayer group, today it is one of the leading producer of crop protection products having three business division namely crop protection, environmental science and bioscience.

Bayer CropScience has employee strength of 17,800 people located in more than 120 countries.

Business Divisions

Crop protection- This division of company focuses on manufacturing herbicides, insecticides, fungicides and seed treatment. Company markets a range of insecticides under the name Confidor. Its fungicide unit is focused on cereals, industrial crops and pathogens. Company hold no.1 position in seed treatment segment.

Environmental Science- This division is engaged on developing innovative products and services in area of on pest management, vector and locust control and weed control solutions. It has developed crop protection active ingredients catering customer of non-agricultural pest control markets. This division is focused on catering individual and commercial customers.

Bioscience- Bayer focuses on plant biotechnology and plant breeding techniques to enhance the quality of crops and vegetables.

Milestones:

2011- New fungicidal seed treatment, active ingredient Penflufen, is registered in the first market (UK, potato cultivation, product Emestoâ„¢)
2011- The new LifeNet® mosquito nets which, for the first time, have directly integrated the active ingredient into a polypropylene fiber, receive an interim recommendation from the World Health Organization.
2011- Acquisition of US-based Hornbeck Seed Company (US soybean seed market)
2010- Bayer CropScience signs several collaboration agreements under its BioScience business unit: One example is the collaboration agreement with Evogene, to improve wheat seed.
2010- Nunhems, the vegetable seed business of Bayer CropScience, expands research and seed production. It invests EUR 12 million in its research facilities in the Netherlands and US$ 30 million in a new seed processing facility in the United States.
2010- New herbicide Indaziflam is registered
2010- New fungicidal active ingredient Bixafen registered in first market (UK)
2010 -New rice fungicide Isotianil is granted regulatory approval in Japan (product Routine®)
2009- Bayer CropScience is first to sequence the genome of rapeseed/canola – This milestone will speed up research and breeding programs.
2009- Bayer CropScience acquires US biotech company Athenix Corp. (Trait platform with extensive product pipeline to deliver innovative solutions).
2009- Start of a long-term cooperation with leading Australian research institute, CSIRO – Expansion of global R&D activities in cereal seeds and traits to accommodate this new key crop
2009- The US Department of Agriculture grants approval for Bayer CropScience’s GlyTol™ cotton technology.
2009- New fungicidal active ingredient Fluopyram strengthens product portfolio (product Luna®, to combat fungal pathogens)
2009- Bayer CropScience consolidates European Plant Biotechnology Research in Ghent – Focus will be on stress tolerance, increasing yields and optimized quality traits in plants in the future
2009- Bayer CropScience acquires certain biological products for the crop protection business from AgroGreen.
2009- Bayer CropScience presents the new herbicidal active ingredient, Indaziflam
2009- Launch of herbicide-tolerance technology for soybeans in the United States
2008- “Baylab plants” lab for schools opens in Monheim: Bayer CropScience encourages students’ interest in science and new technologies
2008 -Thiencarbazone-methyl is registered in first market (corn herbicide)
2008 -The world’s first hybrid rice variety, resistant to bacterial leaf blight – Bayer CropScience launches new high-yielding rice variety in India

• Continued world market leadership in insecticides:Our excellence in innovation and long history in insecticides is underpinning our leadership position in the global insecticides market

• Successful in strategic fungicides markets:Our fungicide Business unit is focused on three strategic segments: cereals, industrial crops and on some specific family of pathogens affecting mainly grapes, vegetables and potatoes

• Innovation and expertise in herbicides:Bayer CropScience has a strong position on the global herbicide market and is a leader on the key cereals, corn, sugar beet and rice markets.

• Number 1 in seed treatment:Seed treatment is one of the most efficient and most environmentally compatible crop protection techniques. Bayer CropScience´s leading position in seed treatment is based on our well-balanced, extensive portfolio. -



Market Cap: 14,852 Cr.
Current Price: 4,326
52 weeks High / Low 4781.90 / 3700.00
Book Value: 570.58
Stock P/E: 51.62
Dividend Yield: 0.42 %
ROCE: 21.64 %
ROE: 15.64 %
Sales Growth (3Yrs): -9.53 %
Listed on BSE and NSE
Company Website
Face Value: 10.00
Industry PBV:
EPS: 83.79
Graham: 1,037
Debt to equity: 0.00
Book value: 570.58
Price to Earning: 51.62
PEG Ratio: 71.69
Earning Power: 17.77 %
Return on equity: 15.64 %
Pledged percentage: 0.00 %
Intrinsic Value: 96,116
Industry PE:
Piotroski score: 6.00
Volume: 3,386
Market cap to quarterly profit: 104.08
Market Capitalization: 14,852 Cr.
Price to book value: 7.58
Return on assets: 14.99 %
Debt: 0.00 Cr.
Interest Coverage Ratio: 33.87

Johnson Controls-Hitachi Air Condition. India Ltd

Hitachi Home and Life Solutions (India), popularly known as Hitachi, is engaged in manufacturing a range of electronic home solutions.

Hitachi Home and Life Solutions (India), incorporated in 1984, is a subsidiary of Hitachi Home & Life Solutions Inc, Japan. The company is among the leading air-conditioning companies in India, which exports to SAARC, Middle East and few more countries globally.

Headquartered in Ahmedabad (Gujarat), the company's manufacturing unit are located at Kadi (Gujarat) and Jammu. The company has installed capacity of 250,000 units a year.

Hitachi Home & Life has a marketing network of 18 branches, 250 sales and service dealers, more than 800 showroom dealers and 350 service points. 

Products

Air-Conditioning- The company produces range of products such as window ACs, split ACa, tower and packaged air conditioners

Hitachi manufactures 2- and 3-door refrigerators. It also manufactures fully automatic machines.

Milestones

1984- The company was incorporated as Acquest Air conditioning Systems.

1991- The company launched its first side throw Air Conditioner (AC).

1992- The company launched the first Hi Wall Mounted Split AC.

1996- The company introduced the first ceiling mounted split AC. 

1997- It launched its first Home AC brand – Nidra.

1999- The company launched 'Hitachi' brand of airconditioners in India.  

2001- Hitachi conducted first ever mass marketing of ACs with remote microprocessor controlled intelligence – Logicool.

2003- The company changed its name to Hitachi Home and Life Solutions (India).

2004- It introduced small split ACs in the world by using Lambda technology and named it as Hitachi Atom.

It introduced the most powerful and silent window AC using Twin Turbo Technology and named it as Quadricool.

2005- Hitachi launched Quadricool -- a window AC that used twin motor technology.

For a cleaner and healthier environment, Hitachi launched UV Fresh technology in Atom.

The company launched Atom + One technology in split ACs that would cool two rooms with one unit.

The company also launched Atom XL - A small cooling solution for the large areas.

It introduced Hitachi refrigerators in India

The company launched fully automatic washing machines in India.

2010
Launched i-TEC, India's First Inverter airconditioner which is made in India & designed for 520 C with Hitachi's patented PAM technology
Launched Fully loaded Kaze range of air conditioners for the mass premium segment
Started manufacturing of water cooled chiller of 40 HP – 120 HP capacities in India
Introduced Company Owned and Company Operated Service Centres - Hitachi Customer Satisfaction (HCS)

2011
Launched i-Clean, India's  First air conditioner with Automatic filter cleaning technology by which it cleans its filter automatically
Launched Summer, India's  First 5 star rated Window air conditioner 

2012
Introduced India's First star rated Cassette air conditioner
Introduced  5 star rated Summer TM window air conditioner with twin motor technology
Introduced Inverter technology in refrigerators

2013
Launched i-Clean Inverter AC and i-Clean Hot & Cold Inverter AC
Launched India's First French Door Bottom Freezer Refrigerator.

Market Cap: 4,871 Cr.
Current Price: 1,791
52 weeks High / Low 2750.00 / 1505.00
Book Value: 213.47
Stock P/E: 54.17
Dividend Yield: 0.08 %
ROCE: 29.31 %
ROE: 20.56 %
Sales Growth (3Yrs): 11.59 %
Listed on BSE and NSE
Company Website
Face Value: 10.00
Industry PBV:
EPS: 33.10
Graham: 398.73
Debt to equity: 0.02
Book value: 213.47
Price to Earning: 54.17
PEG Ratio: 1.19
Earning Power: 11.08 %
Return on equity: 20.56 %
Pledged percentage: 0.00 %
Intrinsic Value: 627.76
Industry PE:
Piotroski score: 8.00
Volume: 1,480
Market cap to quarterly profit: 9,940
Market Capitalization: 4,871 Cr.
Price to book value: 8.39
Return on assets: 17.59 %
Debt: 12.66 Cr.
Interest Coverage Ratio: 100.83

Gillette India Ltd

Gillette India Ltd
Gillette India incorporated 1984, is a renowned player in FMCG industry. The company is in the business of manufacturing Blades and Razors, Oral care and Portable Power. Company has created brands like Duracell, Oral-B, MACH3 Turbo and 7o’clock. The Company's manufacturing units are located at Bhiwadi in Rajasthan and Baddi in Himachal Pradesh.

Milestone - See more at: https://www.moneyworks4me.com/indianstocks/large-cap/fmcg/household-personal-products/gillette-india/company-info#decision-maker-anchor-link

52 Week High / Low (Rs) 7100.00/6200.00 All Time High / Low (Rs) 7196.90/40.00 Volume Traded 47 Market Cap (Rs. Cr.) 21,157 Equity (Rs. Cr.) 32.59 Face Value (Rs) 10 Industry PE 60.89 - See more at: https://www.moneyworks4me.com/indianstocks/large-cap/fmcg/household-personal-products/gillette-india/company-info#decision-maker-anchor-link

Market Cap: 21,162 Cr.
Current Price: 6,494
52 weeks High / Low 7100.00 / 6200.00
Book Value: 213.00
Stock P/E: 91.99
Dividend Yield: 0.35 %
ROCE: 59.81 %
ROE: 38.92 %
Sales Growth (3Yrs): -3.65 %
Listed on BSE and NSE
Company Website
Face Value: 10.00
Industry PBV:
EPS: 70.60
Graham: 581.68
Debt to equity: 0.00
Book value: 213.00
Price to Earning: 91.99
PEG Ratio: 4.27
Earning Power: 29.13 %
Return on equity: 38.92 %
Pledged percentage: 0.00 %
Intrinsic Value: 4,829
Industry PE:
Piotroski score: 8.00
Volume: 2,291
Market cap to quarterly profit: 323.83
Market Capitalization: 21,162 Cr.
Price to book value: 30.49
Return on assets: 36.79 %
Debt: 0.00 Cr.
Interest Coverage Ratio: 48.76

Honeywell Automation India Ltd. - One of the top Growth Stocks of India

Honeywell Automation India Ltd

Set up in 1987 as a joint venture between the Tata Group and Honeywell with manufacturing, design and engineering facilities in the industrial city of Pune (160 km southeast of Mumbai), Honeywell Automation is today the market leader in most of the business areas it operates in. In 2004 the joint venture ended, with Honeywell buying out the entire Tata stake.

Honeywell Automation India (HAIL) is a leading provider of integrated automation and software solutions that improve productivity, enhance comfort and ensure safety and security of homes and business premises. With over 2500 employees and an annual turnover of about Rs. 868 crore, HAIL is headquartered in Pune with 8 offices all over India. HAIL is a listed company on the Indian stock exchanges and is part of Honeywell Inc. the technology leader with 120000 employees across 100 countries worldwide.

Honeywell International is a $36 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London and Chicago Stock Exchanges.

Innovation and adaptability are the hallmarks of HAIL and they aim at creating value for customers in an ever-changing market. The company drives the nation's growth by being responsible to its leadership position in running the 'core' business sectors of the Indian economy, be it infrastructure, petrochemicals, refining, chemicals, mining & metals or automobiles and hospitality.

Honeywell's brands can be seen on the thermostats in buildings, in electronic voting machines, process control systems in refineries and factories or as sensors in automobiles.

HAIL has an impressive 36000 sq ft. state-of-the-art manufacturing facility in Pune, and strict adherence to quality and being receptive to customer needs has helped the Company provide innovative solutions, high-end consulting and engineering designs to organizations, both in India and globally, leading to enormous savings to the customers through better productivity, optimal use of materials and energy, lesser wastage and better maintenance of equipment.

Products and Services offered by the company:
Refining, oil and gas, pulp, paper & printing, power generation, power transmission & distribution, chemicals & life sciences, petrochemicals, and metals, minerals and mining.
Fire detection systems, security systems - access control systems, CCTV systems & perimeter control systems.a complete range of high quality and optimal cost engineering,
Software development & programming and hardware designhome and building control products & solutions.
Electromechanical switches, electronic sensors, machine safety, controls, monitoring & lighting: Sensors for test & measurement applications.

Different divisions of the company:
Honeywell Process Solutions: Industry leader in the areas of process knowledge systems, safety systems, simulation technology, wireless field devices, integrated facility and process security systems.
Honeywell Building Solutions: Honeywell Building Solutions (HBS) is the largest and most technically skilled building solutions player in the Indian sub-continent.
Global Engineering Services: Provides a complete range of high quality and optimal cost engineering, software development & programming and hardware design with total focus on quality.
Environmental and Combustion Control : In more than 100 million homes and 5 million buildings worldwide, Honeywell's products, components and systems deliver temperature control, comfort, energy conservation and safety.
Sensing and Control: Provides electromechanical and machine safety switches, electronic and test and measurement sensors and vehicle controls, monitoring and lighting products for transportation, aerospace, military, industrial and medical applications.

Honeywell Security Group Protects millions of homes, businesses and government facilities around the world.

Awards & Achievements:
It is the first automation and control solutions company in India to receive double certifications of ISO 9001 and OHSAS 18001 certifications.
Honeywell Automation India received the Frost & Sullivan Brand Leadership and the Product Leadership Awards in the Indian DCS Industry 2007
Honeywell Safety Manager is first safety system in process industries to Receive NFPA 72 Certification from US certifying body
ISCEA awarded the 2007 Ptak Prize to Honeywell, in recognition of significant Supply Chain improvements through Vision, Business Rules, and Technology.

• Market Cap: 19,484 Cr.
• Current Price: 22,040
• 52 weeks High / Low 24178.00 / 14712.00
• Book Value: 1,779
• Stock P/E: 62.90
• Dividend Yield: 0.15 %
• ROCE: 29.96 %
• ROE: 19.43 %
• Sales Growth (3Yrs): 3.82 %
• Listed on BSE and NSE
• Company Website
• Face Value: 10.00